LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

LLY

1,086.9

+2.13%↑

JNJ

224.41

+0.52%↑

ABBV

218.39

+2.61%↑

UNH

384

+2.26%↑

MRK

115.88

+0.27%↑

Home・Listă Acțiuni・Odonate Therapeutics Inc

O
Odonate Therapeutics Inc

Deschisă

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Odonate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2026, 20:30 UTC

Câștiguri

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 iun. 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 iun. 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 iun. 2026, 23:00 UTC

Achiziții, Fuziuni, Preluări

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 iun. 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 iun. 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 iun. 2026, 21:00 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 iun. 2026, 20:46 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:38 UTC

Câștiguri

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 iun. 2026, 20:21 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:12 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Product Rev $594M

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Loss $177M >PANW

Comparație

Modificare preț

Odonate Therapeutics Inc Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

Despre Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.